Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
Department of Pharmacognosy, College of Pharmacy, Hawler Medical University, Erbil, Iraq.
Ann N Y Acad Sci. 2022 Apr;1510(1):18-35. doi: 10.1111/nyas.14724. Epub 2022 Jan 4.
Chimeric antigen receptor (CAR) therapy is a method directing T lymphocytes against antigens on the surface of tumors, increasing target cell elimination. Genetic engineering enhances the capability of immune cells to detect new antigens expressed on cell surfaces. CAR T cell therapy is a significant breakthrough for treating human malignancies; however, different side effects (e.g., cytokine release syndrome) restrict its application. Improving design and using various combined receptors enhance the performance of these cells. This review discusses limitations and risk factors associated with CAR T cell therapy. We also review some alternative approaches for developing the next generation of CAR T cells.
嵌合抗原受体 (CAR) 疗法是一种指导 T 淋巴细胞针对肿瘤表面抗原的方法,可增加靶细胞的清除率。基因工程增强了免疫细胞检测细胞表面表达的新抗原的能力。CAR T 细胞疗法是治疗人类恶性肿瘤的重大突破;然而,不同的副作用(例如细胞因子释放综合征)限制了其应用。改进设计并使用各种组合受体可提高这些细胞的性能。本文讨论了与 CAR T 细胞疗法相关的局限性和风险因素。我们还回顾了开发下一代 CAR T 细胞的一些替代方法。